Combining TACE and Sorafenib Improves Survival in HCC With PVTT

The addition of TACE to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis.

Related Keywords

China ,Guangzhou ,Guangdong ,Ming Kuang ,Anhui , ,Sun Yat Sen University ,Cancers Symposium ,